Investor Relations
Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.
Explore Our Deck
View our latest corporate presentation, including recent clinical milestones and our strategic vision for long-term growth.
Latest News
Why Your
Participation Matters
Your participation is more than an investment, it is a commitment to advancing innovative therapies that can improve the lives of people living with neurodegenerative diseases. By joining us, you help accelerate critical research and become part of shaping the future of neurological care with meaningful scientific and human impact.
Our Research
IGC-AD1
Is designed to target neuroinflammation, potentially stabilize CB1r function and address neurotransmitter imbalances, all hallmarks associated with agitation in Alzheimer Dementia
CALMA
Welcome to CALMA, a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of IGC-AD1 for treating agitation associated with Alzheimer’s dementia.
TGR-63
A small molecule designed to break down plaque formation in the brain, exhibiting outstanding biocompatibility, the ability to breach the blood–brain barrier, and pre-clinical behavioral efficacy.
A.I.
To mine the depths of decades-worth of Alzheimer’s research, bringing to light novel insights and pioneering advanced treatments faster than ever for a healthier elderliness.